On 9 December 2020, orphan designation EU/3/20/2381 was granted by the European Commission to Granzer Regulatory Consulting & Services, Germany, for (S)-N-(5-(4-(1-(benzo[d][1,3]dioxol-5-yl)ethyl)piperazin-1-yl)-1,3,4-thiadiazol-2-yl)acetamide, hydrochloride salt (also known as ASN90) for the treatment of progressive supranuclear palsy.
(S)-N-(5-(4-(1-(benzo[d][1,3]dioxol-5-yl)ethyl)piperazin-1-yl)-1,3,4-thiadiazol-2-yl)acetamide, hydrochloride salt
Treatment of progressive supranuclear palsy
|Orphan designation status||
|EU designation number||
|Date of designation||
Review of designation
|June 2023||The sponsorship was transferred from Granzer Regulatory Consulting & Services, Germany, to Ferrer Internacional S.A., Spain in June 2023.|
Documents related to this orphan designation evaluation
EU/3/20/2381: Public summary of opinion on orphan designation: (S)-N-(5-(4-(1-(Benzo[d][1,3]dioxol-5-yl)ethyl)piperazin-1-yl)-1,3,4thiadiazol-2-yl)acetamide, hydrochloride salt for the treatment of progressive supranuclear palsy (PDF/180.31 KB)
First published: 27/05/2021
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: